Bavarian Nordic: Smallpox trials

The registry lists 14 Smallpox studies with Bavarian Nordic as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 4Phase 2 9Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Freeze-Dried MVA-BN® Lot Consistency Smallpox TrialCompletedNCT03699124Phase 3Results posted
• Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionCompletedNCT02038881Phase 2Results posted
• A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy SubjectsCompletedNCT01668537Phase 2Results posted
• A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsCompletedNCT01144637Phase 3Results posted
• A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedNCT00857493Phase 2Results posted
• An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesCompletedNCT00686582Phase 2Results posted
• A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic DermatitisCompletedNCT00316602Phase 2Results posted
• Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected PatientsCompletedNCT00316589Phase 2Results posted
• A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsCompletedNCT00316524Phase 2Results posted
• Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive SubjectsCompletedNCT00189969Phase 1
• Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.CompletedNCT00189956Phase 2
• Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy SubjectsCompletedNCT00189943Phase 1
• Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersCompletedNCT00189917Phase 1
• Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected PatientsCompletedNCT00189904Phase 1/2